Literature DB >> 10629637

Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis.

M Correale1, V Giannuzzi, P A Iacovazzi, M A Valenza, S Lanzillotta, I Abbate, M Quaranta, M L Caruso, S Elba, O G Manghisi.   

Abstract

90K/MAC-2BP glycoprotein is a serum tumour marker, member of the scavenger receptor cysteine rich (SRCR) protein superfamily, involved in different immunological mechanisms. In the present study, we determined 90K serum levels by a sandwich enzyme immunoassay using the same monoclonal antibody in 11 chronic active hepatitis (CAH), 48 liver cirrhosis and 36 hepatocellular carcinoma (HCC). In comparison, the same samples were also tested for AFP. According to a cut-off point of 14 micrograms/mL for the 90K, established as 100% of specificity in 50 controls, we observed increasing positivities from CAH to cirrhosis and then to HCC (27%, 50% and 78%, respectively). In cirrhotic patients 90K levels were associated with the presence of anti-HCV antibodies, but not with the degree of liver compromise. Finally, 90K sensitivity was higher than AIFP in all groups of hepatic patients. However, further investigations are needed before proposing 90K as a clinical useful tumour marker in the progression from cirrhosis to HCC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10629637

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy.

Authors:  E C Darcissac; V Vidal; X De La Tribonniere; Y Mouton; G M Bahr
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection.

Authors:  C B Bigger; K M Brasky; R E Lanford
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma.

Authors:  Rui Chen; Yexiong Tan; Min Wang; Fangjun Wang; Zhenzhen Yao; Liwei Dong; Mingliang Ye; Hongyang Wang; Hanfa Zou
Journal:  Mol Cell Proteomics       Date:  2011-04-07       Impact factor: 5.911

Review 4.  Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target.

Authors:  Emily Capone; Stefano Iacobelli; Gianluca Sala
Journal:  J Transl Med       Date:  2021-09-26       Impact factor: 5.531

5.  Prognostic relevance of LGALS3BP in human colorectal carcinoma.

Authors:  Enza Piccolo; Nicola Tinari; Domenica D'Addario; Cosmo Rossi; Valentina Iacobelli; Rossana La Sorda; Rossano Lattanzio; Maurizia D'Egidio; Annalisa Di Risio; Mauro Piantelli; Pier Giorgio Natali; Stefano Iacobelli
Journal:  J Transl Med       Date:  2015-07-30       Impact factor: 5.531

6.  Female sex, high soluble CD163, and low HDL-cholesterol were associated with high galectin-3 binding protein in type 1 diabetes.

Authors:  Eva Olga Melin; Jonatan Dereke; Magnus Hillman
Journal:  Biol Sex Differ       Date:  2019-11-21       Impact factor: 5.027

7.  LGALS3BP: A Potential Plasma Biomarker Associated with Diagnosis and Prognosis in Patients with Sepsis.

Authors:  Meiyan Luo; Qian Zhang; Yingchun Hu; Changfeng Sun; Yunjian Sheng; Cunliang Deng
Journal:  Infect Drug Resist       Date:  2021-07-24       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.